Article
Combined inhibition of the EGFR and mTOR pathways in EGFR wild-type non-small cell lung cancer cell lines with different genetic backgrounds.
Oncology reports - 1 Jun 2013
Huang Yu, Chen Yu, Mei Qin, Chen Yuan, Yu Shiying, Xia Shu
Abstract excerpt
The epidermal growth factor receptor (EGFR) signaling pathway is widely activated in non-small cell lung cancer (NSCLC). However, only a subset of patients with NSCLC is sensitive to EGFR tyrosine kinase inhibitors (TKIs), particularly those with activating EGFR mutations. The mammalian target of...
Topics
- Antineoplastic Agents
- Carcinoma, Non-Small-Cell Lung
- Cell Line, Tumor
- Class I Phosphatidylinositol 3-Kinases
- Drug Resistance, Neoplasm
- Drug Screening Assays, Antitumor
- Drug Synergism
- ErbB Receptors
- Everolimus
- Gefitinib
- Humans
- Lung Neoplasms
- Mutation
- Phosphatidylinositol 3-Kinases
- Proto-Oncogene Proteins c-akt
- Quinazolines
- Signal Transduction
- Sirolimus